ORBi: Detailled Reference

Article (Scientific journals)

Quelle est la nouvelle donne pour soigner les patients diabétiques de type 2 ?

Scheen, André; Paquot, Nicolas

2009 • In Médecine des Maladies Métaboliques, 3 (2), p. 141-146

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/25480

DOI
10.1016/S1957-2557(09)71625-6

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

nouvelle donne pour diab2.pdf

Publisher postprint (101.99 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Cardiovascular prevention; Type 2 diabetes.; oral antidiabetic agents; incretins; guidelines

Abstract :

[fr] Le traitement du diabète de type 2 est une tâche plus difficile qu’il n’y paraît en raison de la complexité de la maladie du point de vue physiopathologique, de l’adhésion imparfaite du patient aux mesures hygiéno-diététiques, de la multiplicité croissante des médicaments disponibles, des imprécisions persistantes quant aux objectifs glycémiques et de la nécessité de proposer une stratégie de prévention cardio-vasculaire multirisques. Même si des directives générales peuvent être proposées, il convient d’individualiser le traitement en essayant d’obtenir le meilleur rapport bénéfices/risques, à un coût raisonnable. Cet article résume la nouvelle donne dans la prise en charge du diabète de type 2 au vu des résultats des dernières grandes études et du dernier document de consensus publié par l’American diabetes association (ADA) et l’European association for the study of diabetes (EASD). Il insiste sur l’importance d’une prise en charge globale individualisée et sur l’éducation thérapeutique à la fois des soignants et des soignés.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Paquot, Nicolas ; Université de Liège - ULiège > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine)

Language :

French

Title :

Quelle est la nouvelle donne pour soigner les patients diabétiques de type 2 ?

Publication date :

2009

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Publisher :

Elsevier Masson

Volume :

3

Issue :

2

Pages :

141-146

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://www.em-consulte.com/revue/mmm

Available on ORBi :

since 12 October 2009

Statistics

Number of views

109 (8 by ULiège)

Number of downloads

5 (1 by ULiège)

More statistics

Scopus citations^®

8

Scopus citations^®
without self-citations

0

OpenCitations

1

OpenAlex citations

3

Bibliography

Numéro spécial. Le diabète sucré dans tous ses états. Rev Med Liège 2005;60:269-631 (accessible online sur le site : http://www.rmlg.ulg.ac.be).
Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-46.
Virally M, Blicklé JF, Girard J, et al. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab 2007;33:231-44.
Halimi S. Nouvelles stratégies thérapeutiques dans le diabète de type 2 ? Presse Med 2005;34:1287-92.
IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006;23:579-93.
American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009;32(Suppl 1):S13-61.
Scheen AJ. New therapeutic approaches in type 2 diabetes. Acta Clin Belg 2008;63:402-7.
Radermecker RP, Philips JC, Jandrain B, et al. Contrôle glycémique et morbi-mortalité cardiovasculaire chez le patient diabétique de type 2. Résultats des études ACCORD, ADVANCE et VA-Diabetes. Rev Med Liège 2008;63:511-8.
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30.
Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated haemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31.
The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in Veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events : implications of the ACCORD, ADVANCE, and VA Diabetes trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009;119:351-7.
Monnier L, Benichou M, Charra-Ebrard S, et al. An overview of the rationale for pharmacological strategies in type 2 diabetes: from the evidence to new perspectives. Diabetes Metab 2005;31:101-9.
Halimi S. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients? Diabetes Metab 2008;34(Suppl 2):S91-5.
Consoli A, Gomis R, Halimi S, et al. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 2004;30:509-16.
Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43 [Erratum in: N Engl J Med 2007;356:1387-8].
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705.
Scheen AJ. Exenatide once weekly in type 2 diabetes (comment). Lancet 2008;372:1197-8.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
Dormandy J, Charbonnel B, Eckland DJA, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Update regarding the thiazolidinediones. Diabetologia 2008;51:8-11. [Erratum in: Diabetologia 2008;51:522].
Holman RR, Thorne KI, Farmer AJ, et al; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30.
Monnier L, Colette C. Fasting glucose and postprandial glycemia: which is the best target for improving outcomes? The Apollo and 4-T Trials. Expert Opin Pharmacother 2008;9:2857-65.
Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs 2005;65:325-40.
Charbonnel B, Bouhanick B, Le Feuvre C; Groupe de Travail SFC/ALFEDIAM. Recommandations sur la prise en charge du patient diabétique vu par le cardiologue. Diabetes Metab 2004;30:S2-24.
Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91.
Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003;63:1165-84.
Laville M, Romon M, Chabrier G, et al. Recommendations regarding obesity surgery. Obes Surg 2005;15:1476-80.
Scheen AJ. Place de la chirurgie bariatrique dans le traitement de l'obésité. In: Grimaldi A, éditeur. Traité de diabétologie, 2e édition. Paris:Médecine- Sciences Flammarion;2009. p.387-94.
Vetter ML, Cardillo S, Rickels MR, Iqbal N. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 2009;150:94-103.
Bose M, Oliván B, Teixeira J, et al. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence? Obes Surg 2009;19:217-29.
DePaula AL, Macedo AL, Motta BR, Schraibman V. Laparoscopic ileal interposition associated to a diverted sleeve gastrectomy is an effective operation for the treatment of type 2 diabetes mellitus patients with BMI 21-29. Surg Endosc 2008, Oct 2 [Epub ahead of print].

Similar publications